ANC-501 Oral Capsules as Adjunctive Treatment for Major Depressive Disorder

Study Description

The ANC-501 study is a Phase 2 clinical trial that assesses the safety, tolerability, pharmacokinetics, and effectiveness of ANC-501 oral capsules as adjunctive treatment for patients diagnosed with major depressive disorder.

Study Details

Registry ID:

NCT05439603

Conditions:

Major Depressive Disorder

Phase:

Phase 2

Target Enrollment:

15 participants

Start Date:

September 19, 2022

Age Range:

18–65 years

Healthy Volunteers:

No

Study Locations (9 sites)

• Clinilabs Drug Development Corporation
  Eatontown, New JerseyUnited States, United States
• Innovative Clinical Research, Inc.
  Lauderhill, FloridaUnited States, United States
• Clinilabs Drug development Corporation
  New York, New YorkUnited States, United States
• Richmond Behavioral Associates
  Staten Island, New YorkUnited States, United States
• Combined Research Orlando
  Orlando, FloridaUnited States, United States
• Combined Research Orlando Phase I-IV
  Orlando, FloridaUnited States, United States
• Florida Behavioral Medicine
  Largo, FloridaUnited States, United States
• Conrad Clinical Research
  Edmond, OklahomaUnited States, United States
• ATP Clinical Research
  Orange, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →